Elekta declines to continue to participate in linear accelerator bidding process in Brazil

Stockholm, October 22, 2013 – Elekta has declined to continue to participate in
a linear accelerator bidding process at the Ministry of Health in Brazil. During
a reverse auction, the price for 80 linear accelerators, a customer service and
support package, as well as project management, comprehensive software solutions
and brachytherapy equipment, went below BRL 120 million (USD 55 million) which
includes 5% tax – a point that Elekta could not commit to.
“We decided we had to decline participation in this tender when the price went
to unsustainable levels. This is a program where we believe Brazil will require
modern digital linear accelerator systems. The tender includes long-term service
commitments, as well as training and additional machines. Elekta does not
consider it possible to deliver the right quality and support to our Brazilian
customer base at that price level,” says Elekta President and CEO, Tomas
Puusepp.

Puusepp added: “Brazil continues to be a growth market for us, with many
patients that will need access to modern radiation therapy in this decade.
Despite our decision to decline participation in this particular tender, Elekta
will continue to invest in the development and modernization of Brazilian cancer
care.”

# # #

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, e-mail: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 12:00 CET on October 22, 2013.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both healthcare providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,500 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on the Nordic Exchange under the ticker STO: EKTAB. Website:
www.elekta.com.